Friday, 06 Dec 2019

You are here

TNF Inhibitor Induced Psoriasis

Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis. Although the rate of this adverse event is estimated to be 1/1000, it occurs with all TNFi and occurs in rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and even psoriasis patients receiving TNF inhibitors.

A systematic review of published cases of TNF-α inhibitor-induced psoriasis identified 88 articles with 216 cases of new-onset TNF-α inhibitor-induced psoriasis.

The mean age at psoriasis onset was 38.5 years. The most commonly affected were Crohn disease (40.7%) and rheumatoid arthritis (37.0%). Onset of TNFi-induced psoriasis occurred after an average of 14.0 months of TNFi therapy, with 70% noting onset within the first year.  

Affected patients were primarily taking infliximab (62.5%) or adalimumab (21.8%) and few were treated with etanercept (14.4%).

Skin presentations were mixed in 26.9% of patients The most common presentations included plaque (44.8%), palmoplantar pustular (36.3%) psoriasism and psoriasiform dermatitis (19.9%), severe scalp involvement (7.5%), and generalized pustular psoriasis (10.9%). The lesions were equally distributed on the soles, extremities, palms, scalp, and trunk.  Histopathology revealed primarily plaque psoriasis (54.9%) and pustular psoriasis (33.3%).

Although topical therapy was used in most, the most effective regimens were: 1) 47.7% TNFi discontinuation lead to resolution or improveent in 94%; 2)  36.7% switched TNFi inhibitors and nearly 55% improved or resolved; and 3) 32.9% continued therapy with 33% resolved and 57% improving their psoriasis.

Mechanisms underlying this adverse event are not well understood.

The authors suggest that skin-directed therapies works n many cases does and that cessation of TNFi treatment will be needed in a minority of patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

Spondyloarthritis Affects Pregnancy Outcomes

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

IL-17 Inhibitors In Non-Radiographic Axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Psoriatic Arthritis at ACR 2019

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

New Treatments in Axial SpA from #ACR2019

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS. The third area is the use of dual anti-IL17A and 17F drug bimekizumab in radiographic.